2i0h: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2i0h.png|left|200px]] | [[Image:2i0h.png|left|200px]] | ||
{{STRUCTURE_2i0h| PDB=2i0h | SCENE= }} | {{STRUCTURE_2i0h| PDB=2i0h | SCENE= }} | ||
===The structure of p38alpha in complex with an arylpyridazinone=== | ===The structure of p38alpha in complex with an arylpyridazinone=== | ||
{{ABSTRACT_PUBMED_16945533}} | {{ABSTRACT_PUBMED_16945533}} | ||
==About this Structure== | ==About this Structure== | ||
[[2i0h]] is a 1 chain structure of [[Mitogen-activated protein kinase]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2I0H OCA]. | |||
==See Also== | |||
*[[Mitogen-activated protein kinase|Mitogen-activated protein kinase]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:016945533</ref><ref group="xtra">PMID:017070898</ref><references group="xtra"/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Mitogen-activated protein kinase]] | [[Category: Mitogen-activated protein kinase]] | ||
| Line 37: | Line 28: | ||
[[Category: Inhibitor design]] | [[Category: Inhibitor design]] | ||
[[Category: Serine/threonine kinase]] | [[Category: Serine/threonine kinase]] | ||
[[Category: Transferase]] | |||
Revision as of 14:19, 27 July 2012
The structure of p38alpha in complex with an arylpyridazinoneThe structure of p38alpha in complex with an arylpyridazinone
Template:ABSTRACT PUBMED 16945533
About this StructureAbout this Structure
2i0h is a 1 chain structure of Mitogen-activated protein kinase with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See AlsoSee Also
ReferenceReference
- ↑ Natarajan SR, Heller ST, Nam K, Singh SB, Scapin G, Patel S, Thompson JE, Fitzgerald CE, O'Keefe SJ. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5809-13. Epub 2006 Aug 30. PMID:16945533 doi:10.1016/j.bmcl.2006.08.074
- ↑ Lahiri SD, Zhang G, Dunaway-Mariano D, Allen KN. Diversification of function in the haloacid dehalogenase enzyme superfamily: The role of the cap domain in hydrolytic phosphoruscarbon bond cleavage. Bioorg Chem. 2006 Dec;34(6):394-409. Epub 2006 Oct 27. PMID:17070898 doi:10.1016/j.bioorg.2006.09.007